Drug pricing

News

A new FTC report claims that pharmacy benefit managers generated $7.3bn by marking up specialty generics used to treat diseases like cancer and HIV.

News

Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.

News

Legislation that would introduce big changes for pharmacy benefit managers (PBMs) is inching closer to realisation in the US Congress.

News

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

News

Bristol-Myers Squibb has become the latest pharma in the US to file a legal challenge to a block on a 340B drug rebate model opposed by HRSA.

Market Access

The journey to global market access for innovative therapies is fraught with challenges that vary significantly across the world.